Wellgistics Health Inc (WGRX)
NASDAQ:WGRX
Want to see WGRX full AI Analyst Report?
Top Page
Wellgistics Health Inc
(NASDAQ:WGRX)
Select Model
Select Model
Rating:43Neutral
Price Target:
$3.50
▲(2400.00% Upside)
Action:Reiterated
Date:06/13/26
The score is driven primarily by weak financial performance (sharp revenue decline, deeply negative margins, negative equity, and continued cash burn). Technicals also weigh on the score with the stock trading well below major moving averages and negative MACD. Corporate events are mixed—liquidity actions and regained bid compliance help, but equity-compliance and dilution/solvency risks remain significant; valuation provides limited support due to losses and no dividend yield.
Positive Factors
Integrated AI + blockchain platform
Wellgistics is pursuing an integrated AI and blockchain stack (EinsteinRx, PharmacyChain) plus patents (QOLPOM) to own data, verification and patient relationships. That vertical strategy can create durable platform advantages, proprietary data flywheels and differentiated services for pharmacies and payors.
Negative Factors
Sharp revenue and margin deterioration
Steep revenue declines paired with deeply negative gross and net margins indicate structural problems with pricing, cost of goods sold or product mix. Such deterioration undermines operating leverage, requires significant remediation to restore profitability, and makes scaling the platform economically challenging.
Read all positive and negative factors
Positive Factors
Negative Factors
Integrated AI + blockchain platform
Wellgistics is pursuing an integrated AI and blockchain stack (EinsteinRx, PharmacyChain) plus patents (QOLPOM) to own data, verification and patient relationships. That vertical strategy can create durable platform advantages, proprietary data flywheels and differentiated services for pharmacies and payors.
Read all positive factors
Wellgistics Health Inc (WGRX) vs. SPDR S&P 500 ETF (SPY)
Market Cap
$5.70M
Dividend YieldN/A
Average Volume (3M)28.82M
Price to Earnings (P/E)―
Beta (1Y)0.68
Revenue Growth-51.59%
EPS Growth-25.99%
CountryUS
Employees31
SectorHealthcare
Sector Strength45
IndustryMedical - Distribution
Share Statistics
EPS (TTM)N/A
Shares Outstanding2,513,425
10 Day Avg. Volume1,367,507
30 Day Avg. Volume28,820,997
Financial Highlights & Ratios
PEG Ratio>-0.01
Price to Book (P/B)-2.28
Price to Sales (P/S)1.22
P/FCF Ratio-2.61
Enterprise Value/Market Cap6.54
Enterprise Value/Revenue2.66
Enterprise Value/Gross Profit-3.54
Enterprise Value/Ebitda-0.70
Forecast
1Y Price TargetN/A
Price Target UpsideN/A
Rating ConsensusN/A
Number of Analyst Covering0
EPS Forecast (FY)N/A
Revenue Forecast (FY)N/A
Wellgistics Health Inc Business Overview & Revenue Model
Company Description
Wellgistics Health, Inc. functions as a primary wholesaler and distributor of pharmaceutical products throughout the United States, catering to both drug manufacturers and independent retail pharmacies. Its extensive product catalog includes a var...
How the Company Makes Money
null...
Wellgistics Health Inc Financial Statement Overview
Summary
Income Statement
8
Very Negative
Balance Sheet
12
Very Negative
Cash Flow
18
Very Negative
| Breakdown | TTM | Dec 2025 | Dec 2024 | Dec 2023 | Dec 2022 |
|---|---|---|---|---|---|
Income Statement | |||||
| Total Revenue | 14.03M | 23.34M | 18.13M | 0.00 | 32.78M |
| Gross Profit | -10.52M | -9.64M | 1.77M | 0.00 | 5.75M |
| EBITDA | -53.11M | -77.98M | -4.91M | -2.88M | -369.03K |
| Net Income | -76.59M | -101.27M | -6.86M | -2.90M | -2.74M |
Balance Sheet | |||||
| Total Assets | 30.13M | 30.46M | 57.33M | 338.36K | 0.00 |
| Cash, Cash Equivalents and Short-Term Investments | 51.73K | 42.57K | 1.03M | 1.36K | 0.00 |
| Total Debt | 28.73M | 24.58M | 25.11M | 700.00K | 0.00 |
| Total Liabilities | 45.19M | 42.91M | 50.60M | 3.24M | 5.25K |
| Stockholders Equity | -15.06M | -12.45M | 6.73M | -2.90M | -5.25K |
Cash Flow | |||||
| Free Cash Flow | -12.90M | -10.86M | -1.60M | -349.14K | 0.00 |
| Operating Cash Flow | -12.92M | -10.86M | -1.22M | -349.14K | 0.00 |
| Investing Cash Flow | -813.49K | -881.53K | 469.07K | 0.00 | 0.00 |
| Financing Cash Flow | 11.27M | 10.75M | 1.78M | 350.50K | 0.00 |
Wellgistics Health Inc Risk Analysis
Wellgistics Health Inc disclosed 64 risk factors in its most recent earnings report. Wellgistics Health Inc reported the most risks in the "Finance & Corporate" category.
Finance & Corporate - Financial and accounting risks. Risks related to the execution of corporate activity and strategy
Latest Risks Added 0 New Risks
Wellgistics Health Inc Peers Comparison
UnderperformOutperform
Sector (51)
Name | Overall Rating | Market Cap | P/E Ratio | ROE | Dividend Yield | Revenue Growth | EPS Growth |
|---|---|---|---|---|---|---|---|
73 Outperform | $2.73B | 51.42 | 27.21% | ― | 13.54% | ― | |
64 Neutral | $2.25B | 11.92 | 10.29% | ― | -4.31% | -8.94% | |
51 Neutral | $7.86B | -0.30 | -43.30% | 2.27% | 22.53% | -2.21% | |
43 Neutral | $5.70M | -0.06 | 1545.09% | ― | -51.59% | -25.99% | |
43 Neutral | $3.01M | -0.14 | ― | ― | -17.53% | -221.57% |
* Healthcare Sector Average
WGRX
Wellgistics Health Inc
3.48
-65.52
-94.96%
PBH
Prestige Consumer Healthcare
47.82
-35.83
-42.83%
SNYR
Synergy CHC
0.20
-2.08
-91.40%
GRDN
Guardian Pharmacy Services, Inc. Class A
43.09
23.34
118.18%
Wellgistics Health Inc Corporate Events
Business Operations and StrategyDelistings and Listing ChangesM&A TransactionsRegulatory Filings and Compliance
Wellgistics Regains Nasdaq Bid Compliance Amid Equity Risks
Negative
Jun 12, 2026
Wellgistics Health Inc. disclosed that on April 13, 2026, Nasdaq notified the company that its stockholders’ equity, reported at negative $12.45 million as of December 31, 2025, failed to meet the $2.5 million minimum required for continued ...
Business Operations and StrategyPrivate Placements and Financing
Wellgistics Health Raises Capital Through Convertible Note Financing
Positive
May 29, 2026
On May 27, 2026, Wellgistics Health Inc. entered into a private financing with accredited investors, issuing $21.13 million in convertible notes for $16.91 million in cash proceeds at a 20% discount, alongside long-dated PIPE warrants, with the no...
Business Operations and Strategy
Wellgistics details blockchain-based, AI-driven healthcare infrastructure strategy
Positive
May 21, 2026
On May 21, 2026, Wellgistics Health Inc. issued a shareholder letter outlining how recent strategic transactions are designed to create vertically integrated healthcare infrastructure built on blockchain technology. The company argues that its AI ...
Business Operations and StrategyExecutive/Board ChangesM&A TransactionsPrivate Placements and FinancingRegulatory Filings and ComplianceStock Split
Wellgistics Health Announces Transformative AI Healthcare Partnership Deal
Positive
May 21, 2026
On May 20, 2026, Wellgistics Health, Inc. signed a fully binding letter of intent with EOS Technology Holdings, Scilex Holding, Datavault AI, HealthBridge Advisors and Fortitude Advisors for a complex transaction involving QOLPOM/QLPM intellectual...
Business Operations and StrategyFinancial Disclosures
Wellgistics Health Reports Revenue Growth and Narrowed Loss
Positive
May 19, 2026
Wellgistics Health reported first-quarter 2026 results on May 19, 2026, highlighting that revenue rose from $0.486 million in the fourth quarter of 2025 to $0.929 million, while preliminary monthly revenue from its Wellgistics Pharmacy segment inc...
Financial Disclosures
Wellgistics Health Schedules First-Quarter 2026 Earnings Release
Neutral
May 19, 2026
Wellgistics Health, Inc., a healthcare technology and pharmaceutical distribution firm, operates an integrated platform that links thousands of pharmacies with hundreds of drug manufacturers to streamline prescription fulfillment. Its AI-powered E...
Business Operations and StrategyRegulatory Filings and ComplianceShareholder Meetings
Wellgistics Health Withdraws Proxy Amid Strategic Review
Neutral
May 18, 2026
On May 18, 2026, Wellgistics Health, Inc. requested the withdrawal of its Preliminary Proxy Statement on Schedule 14A, which had been filed on May 14, 2026 and related to a special meeting of stockholders. The company chose not to move forward wit...
Business Operations and StrategyPrivate Placements and Financing
Wellgistics Health Enters Forbearance Agreement to Manage Debt
Negative
May 7, 2026
On May 1, 2026, Wellgistics, LLC and its parent Wellgistics Health, Inc. entered into a forbearance and repayment agreement with lender Marco Capital, Inc., formally acknowledging about $1.77 million in outstanding obligations under a November 22,...
Business Operations and StrategyPrivate Placements and Financing
Wellgistics Forms AI-Driven Pharmacy Access Joint Venture
Positive
Apr 17, 2026
On April 13 and 14, 2026, Wellgistics Health, Inc. entered into a collaboration and definitive joint venture agreement with Kare PharmTech’s subsidiary Kare Rx Hub, creating a new limited liability company called Healthstar in which Wellgist...
Business Operations and StrategyPrivate Placements and FinancingRegulatory Filings and Compliance
Wellgistics Health Ends Settlement, Shifts Financing Strategy
Neutral
Apr 9, 2026
On April 3, 2026, Wellgistics Health, Inc. terminated a Settlement Agreement and Stipulation dated January 28, 2026, with Silverback Capital Inc., under which it had already issued 6,866,000 common shares in reliance on Section 3(a)(10) of the Sec...
Private Placements and Financing
Wellgistics Health Raises Capital via Private Note Financing
Positive
Apr 7, 2026
On April 1, 2026, Wellgistics Health, Inc. entered into a private note purchase agreement with accredited investors to issue up to $1.25 million in promissory notes, carrying a 20% original issue discount for total proceeds of $1 million and matur...
Glossary
BuyA stock rated as a "Buy" is expected to perform better than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock is likely to deliver higher returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
HoldA stock rated as a "Hold" is expected to perform in line with the overall market or a specific benchmark. This rating indicates that the stock is neither particularly compelling nor unfavorable for investment. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
SellA stock rated as a "Sell" is expected to perform worse than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock may deliver lower returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
Disclaimer
This AI Analyst Stock Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in stocks carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.